Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab

Kenro Tanoue, Shingo Tamura, Hitoshi Kusaba, Yudai Shinohara, Mamoru Ito, Kenji Tsuchihashi, Tsuyoshi Shirakawa, Taiga Otsuka, Hirofumi Ohmura, Taichi Isobe, Hiroshi Ariyama, Sakuya Koreishi, Yuzo Matsushita, Hozumi Shimokawa, Risa Tanaka, Kenji Mitsugi, Koichi Akashi, Eishi Baba

Research output: Contribution to journalArticlepeer-review

Abstract

Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio (CAR) as a prognostic marker remains to be clarified. This study aimed to analyze the clinical usability of the CAR in comparison with that of the NLR. 46 R/M HNSCC patients treated with nivolumab were retrospectively analyzed. The optimal cutoff value for the CAR was calculated using receiver operating characteristic curve analysis. The optimal cutoff value for the CAR was set to 0.30. On multivariate analyses, a high CAR was significantly associated with poor overall survival (adjusted HR, 2.19; 95% CI, 1.42-3.47; p < 0.01) and progression-free survival (adjusted HR, 1.98; 95% CI, 1.38-2.80; p < 0.01). The overall response rate and disease control rate for the high CAR patients were lower than for the low CAR patients. The CAR had significantly higher area under the curve values than the NLR at 2 and 4 months. The pretreatment CAR might be an independent marker for prognosis and efficacy in R/M HNSCC patients treated with nivolumab.

Original languageEnglish
Pages (from-to)2741
JournalScientific reports
Volume11
Issue number1
DOIs
Publication statusPublished - Feb 2 2021

Fingerprint

Dive into the research topics of 'Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab'. Together they form a unique fingerprint.

Cite this